Scholarlink

<p>Reversible posterior encephalopathy syndrome (PRES) is a relatively rare clinical disorder characterized by reversible subcortical vasogenic edema. Pituitrin is a common medication for hemoptysis. No cases of PRES induced by pituitrin have been reported. A 52-year-old woman with bronchiectasis and hemoptysis developed hypertension, dizziness, seizures, and hemiplegia during treatment with pituitrin. Head magnetic resonance imaging showed multiple abnormal signal shadows in bilateral parieto-occipital cortex and subcortex, which was diagnosed as PRES. The patient's blood pressure returned to normal with medication, and the patient's symptoms subsequently eased and the MRI changes improved. This is the first reported case, without a history of hypertension, of the treatment of PRES secondary to bronchiectasis with hemoptysis with pituitrin. Our case report suggests that pituitrin may cause damage to the central nervous system, such as PRES. Patients who experience dizziness or other neurological symptoms during treatment with pituitrin should consider this rare complication.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Posterior reversible encephalopathy syndrome due to pituitrin for bronchiectasis with hemoptysis——a case report

  • 期刊论文

  • 发表日期：

    2026年2月23日

查看全文
  • Xianru Peng,
  • Zhongli Li,
  • Haiting Xie,
  • Haobo Shi,
  • Zekui Fang

摘要

Reversible posterior encephalopathy syndrome (PRES) is a relatively rare clinical disorder characterized by reversible subcortical vasogenic edema. Pituitrin is a common medication for hemoptysis. No cases of PRES induced by pituitrin have been reported. A 52-year-old woman with bronchiectasis and hemoptysis developed hypertension, dizziness, seizures, and hemiplegia during treatment with pituitrin. Head magnetic resonance imaging showed multiple abnormal signal shadows in bilateral parieto-occipital cortex and subcortex, which was diagnosed as PRES. The patient's blood pressure returned to normal with medication, and the patient's symptoms subsequently eased and the MRI changes improved. This is the first reported case, without a history of hypertension, of the treatment of PRES secondary to bronchiectasis with hemoptysis with pituitrin. Our case report suggests that pituitrin may cause damage to the central nervous system, such as PRES. Patients who experience dizziness or other neurological symptoms during treatment with pituitrin should consider this rare complication.